Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2024 07:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the...
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 10, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world...
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
December 02, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second...
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
November 26, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world...
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
November 14, 2024 07:00 ET
|
Ocular Therapeutix, Inc.
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of...
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
November 13, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world...
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
November 12, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world...
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
November 06, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the...
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
October 15, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular...
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 09, 2024 16:05 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the...